Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma

Journal of Immunotherapy

Volumn 35, Issue 4, 2012, Pages 359-366

  Tarhini, Ahmad A ^a   Leng, Siyang ^a   Moschos, Stergios J ^a   Yin, Yan ^a   Sander, Cindy ^a   Lin, Yan ^a   Gooding, William E ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

GM CSF; melanoma; PF 3512676; TLR9; vaccine

Indexed keywords

AGATOLIMOD; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; MELAN A; MONOPHENOL MONOOXYGENASE;

ADJUVANT THERAPY; ADULT; AGED; ALLERGIC RHINITIS; ANOREXIA; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; COUGHING; DIAPHORESIS; DIARRHEA; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; INSOMNIA; MALE; MELANOMA; MONOTHERAPY; MUCOSAL INFECTION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PSYCHOSIS; RASH; SIDE EFFECT; SKIN INFECTION; SURVIVAL RATE; SURVIVAL TIME; TASTE AVERSION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; CANCER VACCINES; FEMALE; GP100 MELANOMA ANTIGEN; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; OLIGODEOXYRIBONUCLEOTIDES; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84859909667     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31825481fe     Document Type: Article

References (51)

1. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002; 196: 619-628. (Pubitemid 35024440)
2. Nishimura T, Nakui M, Sato M, et al. The critical role of Th1- dominant immunity in tumor immunology. Cancer Chemother Pharmacol. 2000; 46(suppl): S52-S61.
3. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001; 194: 863-869. (Pubitemid 32983021)
4. Tarhini AA, Kirkwood JM, Krieg AM. Early development of the toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. Expert Opin Drug Discov. 2009; 4: 587-603.
5. Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010; 3: 15-25.
6. Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/- granulocyte-monocyte colony-stimulating factor and/or IFNalpha2bin advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009; 15: 1443-1451.
7. Weiner GJ, Liu HM, Wooldridge JE, et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA. 1997; 94: 10833-10837.
8. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001; 31: 3026-3037. (Pubitemid 32994554)
9. Davis HL, Suparto II, Weeratna RR, et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000; 18: 1920-1924. (Pubitemid 30122855)
10. Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 2003; 21: 2461-2467. (Pubitemid 36561337)
11. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005; 115: 739-746. (Pubitemid 40322250)
12. Leong SP, Enders-Zohr P, Zhou YM, et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma.J Immunother. 1999; 22: 166-174. (Pubitemid 29135901)
13. Yamshchikov GV, Barnd DL, Eastham S, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer. 2001; 92: 703-711. (Pubitemid 32385714)
14. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003; 21: 4016-4026. (Pubitemid 46606217)
15. Liu HM, Newbrough SE, Bhatia SK, et al. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood. 1998; 92: 3730-3736. (Pubitemid 28525200)
16. Slingluff CL Jr, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009; 15: 7036-7044.
17. Sandler AD, Chihara H, Kobayashi G, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003; 63: 394-399. (Pubitemid 36152498)
18. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999; 80: 219-230. (Pubitemid 29001725)
19. Kawabe Y, Ochi A. Programmed cell death and extrathymic reduction of Vbeta8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature. 1991; 349: 245-248. (Pubitemid 21912057)
20. LenardoM, Chan KM, Hornung F, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999; 17: 221-253. (Pubitemid 29241124)
21. Blattman JN, Grayson JM, Wherry EJ, et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003; 9: 540-547. (Pubitemid 36597099)
22. Ahlers JD, Dunlop N, Alling DW, et al. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte- macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol. 1997; 158: 3947-3958. (Pubitemid 127488755)
23. Herr W, Schneider J, Lohse AW, et al. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1- binding melanoma and viral peptide antigens. J Immunol Methods. 1996; 191: 131-142. (Pubitemid 26173515)
24. Herr W, Linn B, Leister N, et al. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods. 1997; 203: 141-152. (Pubitemid 27179612)
25. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002; 25: 97-138. (Pubitemid 34260764)
26. Kim CJ, Dessureault S, Gabrilovich D, et al. Immunotherapy for melanoma. Cancer Control. 2002; 9: 22-30. (Pubitemid 34203256)
27. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte- macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993; 90: 3539-3543. (Pubitemid 23111402)
28. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA. 1998; 95: 13141-13146.
29. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008; 26: 527-534. (Pubitemid 351264344)
30. Harrison BE, Johnson JL, Clough RW, et al. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol. 2003; 26: 354-357. (Pubitemid 36962076)
31. Amer MH, Al-Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978; 42: 660-668. (Pubitemid 8405861)
32. Patel JK, Didolkar MS, Pickren JW, et al. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am JSurg. 1978; 135: 807-810. (Pubitemid 8377329)
33. Bullard DE, Cox EB, Seigler HF. Central nervous system metastases in malignant melanoma. Neurosurgery. 1981; 8: 26-30. (Pubitemid 11146127)
34. Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur J Cancer. 1978; 14: 327-330. (Pubitemid 8310441)
35. Sampson JH, Carter JH Jr, Friedman AH, et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998; 88: 11-20. (Pubitemid 28018958)
36. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322: 494-500. (Pubitemid 20067825)
37. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993; 33: 583-590. (Pubitemid 23161878)
38. Smalley SR, Laws ER Jr, O'Fallon JR, et al. Resection for solitary brain metastasis. Role of adjuvant radiation and prognostic variables in 229 patients. J Neurosurg. 1992; 77: 531-540.
39. Sause WT, Crowley JJ, Morantz R, et al. Solitary brain metastasis: results of an RTOG/SWOG protocol evaluation surgery+RT versus RT alone. Am J Clin Oncol. 1990; 13: 427-432. (Pubitemid 20344521)
40. Kondziolka D, Martin JJ, Flickinger JC, et al. Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer. 2005; 104: 2784-2791. (Pubitemid 41798289)
41. Gaudy-Marqueste C, Regis JM, Muracciole X, et al. Gammaknife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 65: 809-816. (Pubitemid 43795850)
42. Gogas H, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354: 709-718. (Pubitemid 43247141)
43. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005; 23: 8968-8977. (Pubitemid 46217464)
44. Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988; 318: 1557-1563.
45. Krauze MT, Tarhini A, Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol. 2011; 33: 385-391.
46. Phan GQ. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci. 2003; 2003: 8372-8377. (Pubitemid 36842552)
47. Tarhini AA, Cherian J, Moschos SJ, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012; 30: 322-328.
48. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14: 3044-3051.
49. Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005; 65: 8331-8338. (Pubitemid 41330598)
50. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
51. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114: 1537-1544.